Nanoparticle Vaccine for HIV
August 15, 2023 | Terry Sharrer
“Researchers from Fred Hutchinson Cancer Center, Scripps Research, and The International AIDS Vaccine Initiative (IAVI) report that the Phase I IAVA G001 clinical trial to test the safety and immune response of a self-assembling nanoparticle HIV vaccine has exhibited a strong T-cell response in human subjects. . . . . Here we demonstrated strong CD4 T-cell responses, and we went beyond what is normally done by drilling down to identify the T cell epitopes and found several broadly immunogenic epitopes that might be useful for developing boosters and for other vaccines, . . . “ MORE
Image Credit: POZ Magazine